Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Deerfield Private Design Fund II, L.P.. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Deerfield Private Design Fund II, L.P. har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:AVDL / Avadel Pharmaceuticals plc | 952 265 | |
US:ALIM / Alimera Sciences, Inc. | 10% Owner | 728 718 |
US:NVLS / Nivalis Therapeutics, Inc. | 10% Owner | 0 |
US:ASPX / Auspex Pharmaceuticals, Inc. | 10% Owner | 0 |
US:DRNA / Dicerna Pharmaceuticals Inc | 10% Owner | 800 794 |
US:TRIV / TriVascular Technologies, Inc. | 10% Owner | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Deerfield Private Design Fund II, L.P.. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp AVDL / Avadel Pharmaceuticals plc - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i AVDL / Avadel Pharmaceuticals plc. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i AVDL / Avadel Pharmaceuticals plc. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-06-25 | AVDL | Flynn James E | 114 034 | 5,9922 | 114 034 | 5,9922 | 683 315 | 304 | 1.0900 | −559 017 | −81,81 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Deerfield Private Design Fund II, L.P. som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-06-25 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
S - Sale | −114 034 | 952 265 | −10,69 | 5,99 | −683 315 | 5 706 162 | |
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 854 839 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 776 217 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 920 342 | ||||||||
2018-05-04 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
American Depositary Shares |
4 391 302 | ||||||||
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27 530 | 728 718 | 3,93 | 3,04 | 83 774 | 2 217 489 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 27 529 | 4 760 408 | 0,58 | 3,04 | 83 771 | 14 485 922 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68 294 | 701 188 | 10,79 | 3,00 | 204 848 | 2 103 213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 68 294 | 701 188 | 10,79 | 3,00 | 204 848 | 2 103 213 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40 301 | 632 894 | 6,80 | 3,01 | 121 169 | 1 902 859 | |
2015-12-08 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 40 301 | 632 894 | 6,80 | 3,01 | 121 169 | 1 902 859 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53 487 | 592 593 | 9,92 | 3,00 | 160 589 | 1 779 201 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 53 486 | 4 624 284 | 1,17 | 3,00 | 160 586 | 13 883 950 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55 257 | 539 106 | 11,42 | 2,98 | 164 876 | 1 608 584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 55 257 | 539 106 | 11,42 | 2,98 | 164 876 | 1 608 584 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12 882 | 483 849 | 2,74 | 3,05 | 39 273 | 1 475 110 | |
2015-12-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12 883 | 4 515 541 | 0,29 | 3,05 | 39 276 | 13 766 530 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36 625 | 470 967 | 8,43 | 2,98 | 109 241 | 1 404 753 | |
2015-11-10 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 36 625 | 470 967 | 8,43 | 2,98 | 109 241 | 1 404 753 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8 271 | 434 342 | 1,94 | 3,00 | 24 813 | 1 303 026 | |
2015-11-03 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 8 271 | 434 342 | 1,94 | 3,00 | 24 813 | 1 303 026 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13 165 | 426 071 | 3,19 | 2,99 | 39 363 | 1 273 952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 13 165 | 426 071 | 3,19 | 2,99 | 39 363 | 1 273 952 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16 506 | 412 906 | 4,16 | 3,00 | 49 518 | 1 238 718 | |
2015-10-29 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 16 506 | 412 906 | 4,16 | 3,00 | 49 518 | 1 238 718 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17 117 | 396 400 | 4,51 | 3,00 | 51 361 | 1 189 438 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 17 116 | 4 428 091 | 0,39 | 3,00 | 51 358 | 13 286 930 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12 090 | 379 283 | 3,29 | 3,00 | 36 270 | 1 137 849 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 12 091 | 4 410 975 | 0,27 | 3,00 | 36 273 | 13 232 925 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367 193 | 0,27 | 3,00 | 2 925 | 1 101 579 | |
2015-10-26 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 975 | 367 193 | 0,27 | 3,00 | 2 925 | 1 101 579 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80 342 | 366 218 | 28,10 | 3,00 | 241 042 | 1 098 727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 80 342 | 366 218 | 28,10 | 3,00 | 241 042 | 1 098 727 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50 065 | 285 876 | 21,23 | 3,00 | 150 060 | 856 856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 50 065 | 285 876 | 21,23 | 3,00 | 150 060 | 856 856 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64 613 | 235 811 | 37,74 | 2,92 | 188 825 | 689 134 | |
2015-10-21 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 64 613 | 235 811 | 37,74 | 2,92 | 188 825 | 689 134 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71 540 | 171 198 | 71,79 | 2,53 | 180 710 | 432 446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 71 540 | 171 198 | 71,79 | 2,53 | 180 710 | 432 446 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19 817 | 99 658 | 24,82 | 2,50 | 49 542 | 249 145 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 19 816 | 4 131 349 | 0,48 | 2,50 | 49 540 | 10 328 372 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69 536 | 79 841 | 674,78 | 2,30 | 159 724 | 183 395 | |
2015-10-09 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
P - Purchase | 69 536 | 79 841 | 674,78 | 2,30 | 159 724 | 183 395 | |
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
8 483 188 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 451 496 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 622 413 | ||||||||
2015-10-09 | 3 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
4 648 858 | ||||||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | −936 839 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | −817 541 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | −85 962 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | −54 385 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 2 Preferred Stock |
C - Conversion | −385 962 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −1 243 423 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −1 085 085 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −1 401 003 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −869 667 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −2 013 613 | 0 | −100,00 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 77 539 | 832 216 | 10,27 | 14,00 | 1 085 546 | 11 651 024 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 67 666 | 726 242 | 10,27 | 14,00 | 947 324 | 10 167 388 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
P - Purchase | 104 795 | 1 124 740 | 10,27 | 14,00 | 1 467 130 | 15 746 360 | |
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 324 278 | 754 677 | 75,34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 282 984 | 658 576 | 75,34 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 29 755 | 647 152 | 4,82 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 18 825 | 402 062 | 4,91 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 133 597 | 1 019 945 | 15,07 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 430 399 | 430 399 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 375 592 | 375 592 | |||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 484 944 | 617 397 | 366,13 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 301 027 | 383 237 | 366,17 | ||||
2015-06-25 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
C - Conversion | 696 993 | 886 348 | 368,09 | ||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
486 233 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
536 475 | ||||||||
2015-06-16 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock |
593 380 | ||||||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | −973 379 | 0 | −100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | −849 426 | 0 | −100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | −1 182 943 | 0 | −100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | −953 286 | 0 | −100,00 | ||||
2015-05-07 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
U - Other | −490 069 | 0 | −100,00 | ||||
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 192 240 | 973 379 | 24,61 | 56,50 | 10 861 560 | 54 995 914 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 167 760 | 849 426 | 24,61 | 56,50 | 9 478 440 | 47 992 569 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 566 825 | 1 182 943 | 92,00 | 56,50 | 32 025 612 | 66 836 280 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 458 175 | 953 286 | 92,54 | 56,50 | 25 886 888 | 53 860 659 | |
2015-01-28 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 115 000 | 490 069 | 30,66 | 56,50 | 6 497 500 | 27 688 898 | |
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 324 172 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 444 214 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 565 221 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 630 769 | ||||||||
2014-12-22 | 3 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
3 730 242 | ||||||||
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −55 035 | 800 794 | −6,43 | 11,50 | −632 902 | 9 209 131 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −48 027 | 698 822 | −6,43 | 11,50 | −552 310 | 8 036 453 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −18 903 | 275 046 | −6,43 | 11,50 | −217 384 | 3 163 029 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −3 785 | 855 829 | −0,44 | 11,54 | −43 679 | 9 876 267 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −3 303 | 746 849 | −0,44 | 11,54 | −38 117 | 8 618 637 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −14 199 | 293 949 | −4,61 | 11,55 | −163 998 | 3 395 111 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −41 339 | 859 614 | −4,59 | 11,55 | −477 465 | 9 928 542 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −36 074 | 750 152 | −4,59 | 11,55 | −416 655 | 8 664 256 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −1 300 | 308 148 | −0,42 | 11,54 | −15 002 | 3 556 028 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −45 124 | 900 953 | −4,77 | 11,00 | −496 364 | 9 910 483 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −39 377 | 786 226 | −4,77 | 11,00 | −433 147 | 8 648 486 | |
2014-11-25 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −15 499 | 309 448 | −4,77 | 11,00 | −170 489 | 3 403 928 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −30 100 | 0 | −100,00 | 9,33 | −280 833 | ||
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −3 500 | 30 100 | −10,42 | 9,27 | −32 445 | 279 027 | |
2014-11-10 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −180 564 | 33 600 | −84,31 | 9,00 | −1 625 076 | 302 400 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −51 449 | 214 164 | −19,37 | 10,01 | −515 004 | 2 143 782 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −14 464 | 946 077 | −1,51 | 11,02 | −159 393 | 10 425 769 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −12 622 | 825 603 | −1,51 | 11,02 | −139 094 | 9 098 145 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −4 061 | 265 613 | −1,51 | 11,02 | −44 752 | 2 927 055 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −4 968 | 324 947 | −1,51 | 11,02 | −54 747 | 3 580 916 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −246 | 960 541 | −0,03 | 12,00 | −2 952 | 11 528 413 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −215 | 838 225 | −0,03 | 12,00 | −2 580 | 10 060 376 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −69 | 269 674 | −0,03 | 12,00 | −828 | 3 236 627 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −84 | 330 | −20,29 | 12,00 | −1 008 | 3 960 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −11 855 | 960 787 | −1,22 | 12,14 | −143 860 | 11 659 150 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −10 345 | 838 440 | −1,22 | 12,14 | −125 537 | 10 174 469 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −3 328 | 269 743 | −1,22 | 12,14 | −40 385 | 3 273 331 | |
2014-10-15 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
S - Sale | −4 072 | 329 999 | −1,22 | 12,14 | −49 414 | 4 004 538 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | −253 384 | 0 | −100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | −221 118 | 0 | −100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | −71 333 | 0 | −100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | −86 834 | 0 | −100,00 | ||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 75 480 | 261 143 | 40,65 | 11,97 | 903 126 | 3 124 602 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94 520 | 324 524 | 41,09 | 11,97 | 1 130 941 | 3 882 962 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 19 980 | 185 663 | 12,06 | 12,29 | 245 468 | 2 281 000 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 25 020 | 230 004 | 12,21 | 12,29 | 307 388 | 2 825 760 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 340 425 | 593 809 | 134,35 | 12,00 | 4 085 100 | 7 125 708 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 297 075 | 518 193 | 134,35 | 12,00 | 3 564 900 | 6 218 316 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 94 350 | 165 683 | 132,27 | 12,00 | 1 132 200 | 1 988 196 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 118 150 | 204 984 | 136,06 | 12,00 | 1 417 800 | 2 459 808 | |
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 253 384 | 253 384 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 221 118 | 221 118 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 71 333 | 71 333 | |||||
2014-04-22 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 86 834 | 86 834 | |||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | −2 323 086 | 0 | −100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | −2 027 262 | 0 | −100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | −654 002 | 0 | −100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Series E Preferred Stock |
C - Conversion | −796 114 | 0 | −100,00 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 280 350 | 796 591 | 54,31 | 12,00 | 3 364 200 | 9 559 092 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 244 650 | 695 152 | 54,31 | 12,00 | 2 935 800 | 8 341 824 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 78 400 | 223 733 | 53,95 | 12,00 | 940 800 | 2 684 796 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 96 600 | 273 514 | 54,60 | 12,00 | 1 159 200 | 3 282 168 | |
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 516 241 | 796 591 | 184,14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 450 502 | 695 152 | 184,14 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 145 333 | 223 733 | 185,37 | ||||
2014-02-11 |
|
4 | ASPX |
Auspex Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 176 914 | 273 514 | 183,14 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | −572 142 | 0 | −100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | −499 285 | 0 | −100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | −161 071 | 0 | −100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | −196 071 | 0 | −100,00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 400 500 | 972 642 | 70,00 | 15,00 | 6 007 500 | 14 589 630 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 349 500 | 848 785 | 70,00 | 15,00 | 5 242 500 | 12 731 775 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 112 000 | 273 071 | 69,53 | 15,00 | 1 680 000 | 4 096 065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
P - Purchase | 138 000 | 334 071 | 70,38 | 15,00 | 2 070 000 | 5 011 065 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 572 142 | 972 642 | 142,86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 499 285 | 848 785 | 142,86 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 161 071 | 273 071 | 143,81 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 196 071 | 334 071 | 142,08 |